Clinical trials
Clinical High Risk clinical trials
Below are recruiting clinical high risk clinical trials, each written for real people, not researchers. We’re tracking 556 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07505472RecruitingPhase 2/Phase 3
Short radiation plus chemo and immunotherapy for high-risk rectal cancer
This trial tests a new approach for people with locally advanced rectal cancer that has high-risk features. It combines short-course radiation with chemotherapy (CapeOX) and the immunotherapy drug toripalimab, with or without another drug called surufatinib, before surgery. The goal is to see if adding these drugs helps shrink the tumor and improve outcomes.
Changchun, JilinAges 18–75 - NCT07523555RecruitingPhase 1/Phase 2
Dual-Target CAR-T Cells for Blood Cancers That Haven't Responded to Treatment
This study tests a new type of cell therapy called CAR-T cells that are designed to target two different proteins on cancer cells. These cells are made from your own immune cells, trained in the lab, and then put back into your body to fight blood cancers that have come back or stopped responding to previous treatments.
Shenzhen, GuangdongAges 18–75 - NCT07532434Recruiting
Risk-Reducing Surgery for Hereditary Ovarian Cancer
This study follows women who carry gene mutations that increase ovarian cancer risk to understand how preventive surgery affects their health, quality of life, and peace of mind. Researchers will track your outcomes over 3 years to help inform future treatment decisions for others at similar risk.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07575971RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for High-Risk B-Cell Acute Lymphoblastic Leukemia
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target leukemia cells after chemotherapy has put your disease into remission. The goal is to help prevent the leukemia from coming back, especially for patients at high risk of relapse.
Beijing, Beijing MunicipalityAges 18–85 - NCT07580196Recruiting
Comparing lymph node removal approaches in aggressive prostate cancer
This trial compares two surgical approaches for removing lymph nodes during prostate cancer surgery in men with high-risk disease on one side of the prostate. The goal is to determine whether removing lymph nodes from both sides or just one side provides better outcomes.
Rozzano, MilanoAges 18 years+ - NCT07594964RecruitingPhase 1
Safety Study of XH001 Injection for High-Risk Recurrent Solid Tumors
This early-stage trial tests a new injection called XH001 as an additional treatment after surgery for patients with high-risk cancers that have come back. The goal is to check if it's safe and whether it helps prevent the cancer from returning again.
BeijingAges 18–70 - NCT07625553RecruitingPhase 2
Relaxin Agonist to Protect Kidneys During Heart Surgery
This study tests whether a drug called R2R01 can help protect your kidneys during major heart surgery. Heart surgery can sometimes damage the kidneys, and this trial is looking to see if this new medication reduces that risk.
MilanAges 18 years+ - NCT07640048Recruiting
Adjuvant therapy after surgery for high-risk bile duct cancer
This study tests additional treatment given after surgery to remove high-risk intrahepatic cholangiocarcinoma (a type of bile duct cancer). The goal is to reduce the chance the cancer comes back and improve survival in patients whose tumors had concerning features.
BeijingAges 18 years+ - NCT07646145RecruitingPhase 2
Disitamab Vedotin Plus Mitomycin C for HER2-Positive Bladder Cancer
This trial tests a combination of two medications—disitamab vedotin (a targeted therapy) and mitomycin C (a chemotherapy)—for people with early-stage bladder cancer that has a specific protein called HER2. The goal is to prevent cancer from coming back after surgery in people who cannot or will not receive BCG treatment.
Taiyuan, ShanxiAges 18 years+ - NCT07670026RecruitingPhase 2
Stronger treatment after surgery for high-risk glioblastoma
This trial tests a more intense chemotherapy plan for people with glioblastoma who had only partial removal of their tumor or whose tumor grew back quickly. The goal is to see if this approach can improve outcomes.
Hangzhou, ZhejiangAges 18 years+ - NCT07671378RecruitingPhase 2
Study of zanubrutinib plus sonrotoclax for high-risk CLL/SLL
This trial tests a combination of two targeted drugs (zanubrutinib and sonrotoclax) as a first treatment for people with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). It aims to see if this approach works better than standard care by using a test called MRD to guide treatment duration.
Nanjing, JiangsuAges 18–75 - NCT07416344Enrolling by invitation
Heart CT screening for high-risk rural patients
This trial uses a heart CT scan to find people in rural China who are at high risk for heart disease but haven't had a heart attack or stroke yet. The goal is to see if this screening can help guide treatment and prevent future heart problems.
Daqing, HeilongjiangAges 40–75 - NCT07316361Enrolling by invitationEarly Phase 1
Personalized vaccine for high-risk endometrial cancer
This trial tests a personalized vaccine made from your tumor's unique proteins to help your immune system fight high-risk or advanced endometrial cancer. It is given along with your regular cancer treatments.
Thessaloniki, ThessalonikiAges Any age - NCT06542575Enrolling by invitation
Home heart rehab with app after stent
This trial tests a home-based program that uses a smartphone app (digital therapy) to help people with high-risk heart conditions after a stent procedure. The goal is to improve recovery through exercise and lifestyle support, all from home.
Chengdu, SichuanAges 18–75 - NCT04798430Enrolling by invitationPhase 3
Study drug follow-up for LDL reduction in high-risk cholesterol patients
This Phase 3 study looks at the long-term safety and benefit of OLE LIB003 for people with very high cholesterol or heart disease risk who still need lower LDL (“bad cholesterol”). It’s likely a continuation study for participants who already did earlier LIB003 Phase 3 trials.
Evanston, IllinoisAges 10 years+ - NCT06215326Recruiting
Short-term exercise before lung cancer surgery
This trial tests if doing exercise before lung cancer surgery can help people with moderate-to-high risk. Participants will exercise for a short period to see if it improves their recovery.
Guangzhou, GuangdongAges 18 years+ - NCT05893030Recruiting
Monitoring pain and sleep medicines to prevent complications after surgery
This study looks at whether closely monitoring opioid and sleep medicines during and after surgery can lower organ problems and death in older adults at high risk. If you qualify, your team will track how these medicines are given to help keep you safer in the postoperative period.
AmiensAges 75 years+ - NCT05457569Recruiting
Parent support program for babies at high brain risk
This study checks whether a coordinated parent support program delivered after NICU (and after discharge) is practical and helpful. It gathers feedback through interviews with parents and professionals to improve how care and parenting support are organized.
DijonAges 18 years+ - NCT07125417RecruitingPhase 4
Blood thinner comparison after left atrial appendage closure
This study compares two approaches after a left atrial appendage closure (LAAC) procedure: taking no blood thinner versus taking just one antiplatelet medication. It aims to see which option is safer for people with atrial fibrillation who are at risk for bleeding.
Nagoya, Aichi-kenAges Any age - NCT06930573RecruitingPhase 4
AK112 for high-risk liver cancer after surgery
This study tests a new drug called AK112 (a combination antibody targeting two proteins that help tumors grow) after surgery for liver cancer that has a high chance of returning. The goal is to see if it can prevent the cancer from coming back.
Zhengzhou, HenanAges 18–75 - NCT04029363Recruiting
Transcatheter mitral valve procedure for high-surgery-risk patients
This trial studies a newer, catheter-based mitral valve treatment in people with moderate-severe to severe mitral valve leaking who are at high risk for open-heart surgery. It may help improve symptoms and heart function without traditional surgery, but you must meet key heart, anatomy, and safety requirements.
Darlinghurst, New South WalesAges 18 years+ - NCT06276374Recruiting
Dual antiplatelet therapy after carotid artery stenting for high bleeding risk
This trial tests if taking two blood thinners (dual antiplatelet therapy) after a carotid artery stenting procedure is safe and effective for patients who have a higher risk of bleeding. It focuses on people with significant blockages in the neck arteries who are also at increased risk for serious bleeding or brain bleeds.
SeoulAges 19 years+ - NCT06458257Recruiting
Stem cell transplant for high-risk AML with CEBPA mutation
This trial tests whether a stem cell transplant from a donor can help people with a specific type of acute myeloid leukemia (AML) that has a high risk of coming back. It is for patients who have the CEBPA gene mutation and other high-risk features.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06535568Recruiting
Comparing one vs two blood thinners after heart artery balloon treatment
This trial tests whether taking just one blood thinner (clopidogrel) is as safe and effective as taking two (clopidogrel plus aspirin) for older adults or people at high bleeding risk who have had a drug-coated balloon procedure to open blocked heart arteries.
Milan, MIAges Any age
Hear when a new Clinical High Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for clinical high risk?
- Yes. Clin2 currently lists 556 recruiting clinical high risk studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a clinical high risk trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a clinical high risk trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.